CIDeRplusGeneral Information:
| Id: | 5,011 |
| Diseases: |
Diabetes mellitus, type II
- [OMIM]
Insulin resistance |
| Homo sapiens | |
| BTO:0000133 blood serum | |
| article | |
| Reference: | Altmaier E et al.(2014) Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism Eur. J. Epidemiol. 29: 325-336 [PMID: 24816436] |
Interaction Information:
| Comment | For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased. |
|
Formal Description Interaction-ID: 49429 |
drug/chemical compound Beta blocker increases_quantity of drug/chemical compound Pyroglutamine |
| Comment | For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased. |
|
Formal Description Interaction-ID: 49432 |
drug/chemical compound Beta blocker increases_quantity of drug/chemical compound |
| Comment | For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased. |
|
Formal Description Interaction-ID: 49433 |
drug/chemical compound Beta blocker increases_quantity of drug/chemical compound |
| Comment | For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased. |
|
Formal Description Interaction-ID: 49434 |
drug/chemical compound Beta blocker increases_quantity of drug/chemical compound Pyroglutamine |
| Comment | For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased. |
|
Formal Description Interaction-ID: 49435 |
drug/chemical compound Beta blocker increases_quantity of drug/chemical compound Hydroxyisovaleroylcarnitine |
| Comment | For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased. |
|
Formal Description Interaction-ID: 49436 |
drug/chemical compound Beta blocker increases_quantity of drug/chemical compound 2-Methylbutyroylcarnitine |
| Comment | For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased. |
|
Formal Description Interaction-ID: 49437 |
drug/chemical compound Beta blocker decreases_quantity of drug/chemical compound |
| Comment | For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased. |
|
Formal Description Interaction-ID: 49438 |
drug/chemical compound Beta blocker decreases_quantity of drug/chemical compound Dihomo-linoleate |
| Comment | For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased. |
|
Formal Description Interaction-ID: 49440 |
drug/chemical compound Beta blocker decreases_quantity of drug/chemical compound 10-Nonadecenoate |
| Comment | For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased. |
|
Formal Description Interaction-ID: 49441 |
drug/chemical compound Beta blocker decreases_quantity of drug/chemical compound Heptadecanoic acid |
| Comment | For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased. |
|
Formal Description Interaction-ID: 49442 |
drug/chemical compound Beta blocker decreases_quantity of drug/chemical compound Eicosenoic acid |
| Comment | For patients who took beta-blockers increased concentrations of pyroglutamine, homocitrulline, salicylate, and acylcarnitins were observed in the blood serum. In contrast, serotonin, fatty acids and 3-hydroxybutyrate [FA(4:0-OH)] were decreased. |
|
Formal Description Interaction-ID: 49445 |
drug/chemical compound Beta blocker decreases_quantity of drug/chemical compound |
| Comment | For the group of ACE inhibitors four metabolites were identified that significantly associated with the intake of these drugs. While levels of the polypeptide HWESASXX and des-arg(9)-bradykinin were higher in case of medication with ACE inhibitors, lower levels of phenylalanylphenylalanine and aspartylphenylalanine were found. |
|
Formal Description Interaction-ID: 49446 |
drug/chemical compound ACE inhibitor increases_quantity of gene/protein His-Trp-Glu-Ser-Ala-Ser-X-X |
| Comment | For the group of ACE inhibitors four metabolites were identified that significantly associated with the intake of these drugs. While levels of the polypeptide HWESASXX and des-arg(9)-bradykinin were higher in case of medication with ACE inhibitors, lower levels of phenylalanylphenylalanine and aspartylphenylalanine were found. |
|
Formal Description Interaction-ID: 49447 |
drug/chemical compound ACE inhibitor increases_quantity of gene/protein |
| Comment | For the group of ACE inhibitors four metabolites were identified that significantly associated with the intake of these drugs. While levels of the polypeptide HWESASXX and des-arg(9)-bradykinin were higher in case of medication with ACE inhibitors, lower levels of phenylalanylphenylalanine and aspartylphenylalanine were found. |
|
Formal Description Interaction-ID: 49448 |
drug/chemical compound ACE inhibitor decreases_quantity of drug/chemical compound Phe-Phe |
| Comment | For the group of ACE inhibitors four metabolites were identified that significantly associated with the intake of these drugs. While levels of the polypeptide HWESASXX and des-arg(9)-bradykinin were higher in case of medication with ACE inhibitors, lower levels of phenylalanylphenylalanine and aspartylphenylalanine were found. |
|
Formal Description Interaction-ID: 49449 |
drug/chemical compound ACE inhibitor decreases_quantity of drug/chemical compound Asp-Phe |
| Comment | Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively. |
|
Formal Description Interaction-ID: 49450 |
drug/chemical compound Diuretic increases_quantity of drug/chemical compound |
| Comment | Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively. |
|
Formal Description Interaction-ID: 49451 |
drug/chemical compound Diuretic increases_quantity of drug/chemical compound C-glycosyltryptophan |
| Comment | Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively. |
|
Formal Description Interaction-ID: 49455 |
drug/chemical compound Diuretic increases_quantity of drug/chemical compound Glytarylcarnitine |
| Comment | Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively. |
|
Formal Description Interaction-ID: 49456 |
|
| Comment | Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively. |
|
Formal Description Interaction-ID: 49462 |
drug/chemical compound Diuretic increases_quantity of drug/chemical compound |
| Comment | Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively. |
|
Formal Description Interaction-ID: 49463 |
drug/chemical compound Diuretic increases_quantity of gene/protein His-Trp-Glu-Ser-Ala-Ser-X-X |
| Comment | Diuretics showed associations with increased serum levels of pseudouridine, C-glycosyltryptophan, glutaroylcarnitine [C5-DC] and urate. Additional metabolites with a p value smaller than 3.39 x 10-5, namely homocitrulline, HWESASXX (both increased) and phenylalanylphenylalanine (decreased) were already found to associate with beta-blockers and ACE inhibitors, respectively. |
|
Formal Description Interaction-ID: 49464 |
drug/chemical compound Diuretic decreases_quantity of drug/chemical compound Phe-Phe |
| Comment | For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased). |
|
Formal Description Interaction-ID: 49465 |
drug/chemical compound Statin increases_quantity of drug/chemical compound LysoPC(20:4) |
| Comment | For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased). |
|
Formal Description Interaction-ID: 49466 |
drug/chemical compound Statin increases_quantity of drug/chemical compound LysoPE(20:4) |
| Comment | For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased). |
|
Formal Description Interaction-ID: 49467 |
drug/chemical compound Statin decreases_quantity of drug/chemical compound |
| Comment | For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased). |
|
Formal Description Interaction-ID: 49468 |
drug/chemical compound Statin decreases_quantity of drug/chemical compound 1-Palmitoylglycerophosphoinositol |
| Comment | For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased). |
|
Formal Description Interaction-ID: 49469 |
drug/chemical compound Statin decreases_quantity of drug/chemical compound |
| Comment | For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased). |
|
Formal Description Interaction-ID: 49470 |
drug/chemical compound Statin increases_quantity of drug/chemical compound Isobutyrylcarnitine |
| Comment | For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased). |
|
Formal Description Interaction-ID: 49471 |
drug/chemical compound Statin increases_quantity of drug/chemical compound LysoPC(22:6) |
| Comment | For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased). |
|
Formal Description Interaction-ID: 49472 |
drug/chemical compound Statin increases_quantity of drug/chemical compound |
| Comment | For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased). |
|
Formal Description Interaction-ID: 49473 |
drug/chemical compound Statin decreases_quantity of drug/chemical compound |
| Comment | For the statins the resulting metabolites with the lowest p values were 1-arachidonoylglycerophosphocholine [LPC(20:4)], 1-arachidonoylglycerophosphoethanolamine [LPE(20:4)], isobutyrylcarnitine [C3-M], 1-docosahexaenoylglycerophosphocholine [LPC(22:6)], alpha-tocopherol, uridine (all increased), 7-alphahydroxy-3-oxo-4-cholestenoate, 1-palmitoylglycerophosphoinositol [LPI(16:0)], lathosterol and glycochenodeoxycholate (all decreased). |
|
Formal Description Interaction-ID: 49477 |
|
| Drugbank entries | Show/Hide entries for |
| Comment | For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive. |
|
Formal Description Interaction-ID: 49478 |
drug/chemical compound Fibrate increases_quantity of drug/chemical compound 2-Hydroxyisobutyric acid |
| Comment | For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive. |
|
Formal Description Interaction-ID: 49479 |
drug/chemical compound Fibrate increases_quantity of drug/chemical compound |
| Comment | For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive. |
|
Formal Description Interaction-ID: 49480 |
drug/chemical compound Fibrate increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for |
| Comment | For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive. |
|
Formal Description Interaction-ID: 49481 |
drug/chemical compound Fibrate increases_quantity of drug/chemical compound |
| Comment | For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive. |
|
Formal Description Interaction-ID: 49482 |
drug/chemical compound Fibrate increases_quantity of drug/chemical compound |
| Comment | For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive. |
|
Formal Description Interaction-ID: 49483 |
drug/chemical compound Fibrate decreases_quantity of drug/chemical compound Pyroglutamine |
| Comment | For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive. |
|
Formal Description Interaction-ID: 49484 |
drug/chemical compound Fibrate increases_quantity of drug/chemical compound |
| Comment | For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive. |
|
Formal Description Interaction-ID: 49485 |
drug/chemical compound Fibrate increases_quantity of drug/chemical compound |
| Comment | For fibrates most of the significant metabolites showed a positive association: 2-hydroxyisobutyrate [FA(3:0-OH-M)], 3-dehydrocarnitine, riboflavin, pantothenate, indolelactate, carnitine, pipecolate and uridine. Only for one of the resulting metabolites - pyroglutamine - a significant negative association was detected. Pyroglutamine was already observed to associate with the intake of betablockers. However, in contrast to the intake of fibrates, the association between the beta-blockers and the concentration of pyroglutamine was positive. |
|
Formal Description Interaction-ID: 49487 |
|
| Drugbank entries | Show/Hide entries for |